NASDAQ Composite ended the session with Castle Biosciences rising 3.41% to $65.53 on Thursday while nASDAQ Composite fell 0.94% to $13,818.41.
Castle Biosciences today’s close was $65.53, 64.34% below its 52-week high of $107.69.
The company’s growth estimates for the present quarter and the next is a negative 900% and a negative 150%, respectively.
Castle Biosciences’s Revenue
Year-on-year quarterly revenue growth declined by 1.9%, now sitting on 62.65M for the twelve trailing months.
Castle Biosciences’s last day, last week, and last month’s current volatility was 4.47%, 3.40%, and 3.16%, respectively.
Castle Biosciences‘s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 8.64% (day), 6.75% (last week), and 6.05% (last month), respectively.
Castle Biosciences’s Stock Yearly Top and Bottom Value
Castle Biosciences’s stock is valued at $65.53 at 17:12 EST, way under its 52-week high of $107.69 and way above its 52-week low of $26.13.
Castle Biosciences’s Moving Average
Castle Biosciences’s value is under its 50-day moving average of $71.54 and higher than its 200-day moving average of $63.56.
More news about Castle Biosciences.